Y<sub>1</sub> receptor | Neuropeptide Y receptors | IUPHAR/BPS Guide to PHARMACOLOGY

Y1 receptor

Target id: 305

Nomenclature: Y1 receptor

Family: Neuropeptide Y receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

   GtoImmuPdb view: OFF :     Currently no data for Y1 receptor in GtoImmuPdb

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 384 4q31.3-q32 NPY1R neuropeptide Y receptor Y1 26-27,39
Mouse 7 382 8 B3-C2 Npy1r neuropeptide Y receptor Y1 17,44,67
Rat 7 382 16p14 Npy1r neuropeptide Y receptor Y1 16,37,55
Previous and Unofficial Names
NPY-Y1 receptor [55] | FC5 | neuropeptide Y receptor type 1 | Y1-R
Database Links
Specialist databases
GPCRDB npy1r_human (Hs), npy1r_mouse (Mm), npy1r_rat (Rn)
Other databases
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia
Natural/Endogenous Ligands
neuropeptide Y {Sp: Human, Mouse, Rat}
pancreatic polypeptide {Sp: Human} , pancreatic polypeptide {Sp: Mouse} , pancreatic polypeptide {Sp: Rat}
peptide YY {Sp: Human} , peptide YY {Sp: Mouse, Rat, Pig}
Comments: Neuropeptide Y is the principal endogenous agonist
Potency order of endogenous ligands (Human)
neuropeptide Y = peptide YY >> pancreatic polypeptide

Download all structure-activity data for this target as a CSV file

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[125I]PYY (pig) Hs Full agonist 9.1 – 10.2 pKd 39,60
pKd 10.2 [60]
pKd 9.1 [39]
[125I]NPY (human, mouse, rat) Rn Full agonist 9.2 pKd 37
pKd 9.2 [37]
[3H]NPY (human, mouse, rat) Mm Full agonist 8.8 pKd 67
pKd 8.8 [67]
[Leu31,Pro34]NPY Rn Full agonist 10.6 pKi 20
pKi 10.6 [20]
neuropeptide Y {Sp: Human, Mouse, Rat} Rn Full agonist 10.5 pKi 20
pKi 10.5 [20]
peptide YY {Sp: Mouse, Rat, Pig} Rn Full agonist 10.2 pKi 20
pKi 10.2 [20]
[Leu31,Pro34]PYY (human) Rn Full agonist 10.2 pKi 20
pKi 10.2 [20]
NPY {Sp: Pig} Rn Full agonist 10.0 pKi 20
pKi 10.0 [20]
NPY {Sp: Pig} Hs Full agonist 9.7 pKi 60
pKi 9.7 [60]
NPY-(2-36) Rn Full agonist 9.2 pKi 20
pKi 9.2 [20]
pancreatic polypeptide {Sp: Bovine} Rn Full agonist 7.9 pKi 20
pKi 7.9 [20]
pancreatic polypeptide {Sp: Human} Rn Full agonist 7.9 pKi 20
pKi 7.9 [20]
NPY-(13-36) (pig) Rn Full agonist 7.8 pKi 20
pKi 7.8 [20]
NPY-(3-36) (pig) Rn Full agonist 7.7 pKi 20
pKi 7.7 [20]
PYY-(13-36) (mouse, rat, pig) Rn Full agonist 7.5 pKi 20
pKi 7.5 [20]
PYY-(3-36) {Sp: Human} Rn Full agonist 7.4 pKi 20
pKi 7.4 [20]
pancreatic polypeptide {Sp: Rat} Rn Full agonist 7.0 pKi 20
pKi 7.0 [20]
[Leu31,Pro34]NPY Hs Agonist 7.1 pEC50 12
pEC50 7.1 (EC50 7.87x10-8 M) [12]
neuropeptide Y {Sp: Human, Mouse, Rat} Rn Full agonist 8.6 – 8.8 pIC50 37
pIC50 8.6 – 8.8 [37]
[Leu31,Pro34]NPY (pig) Rn Full agonist 8.4 pIC50 15
pIC50 8.4 [15]
[Leu31,Pro34]NPY Rn Full agonist 8.0 – 8.6 pIC50 37
pIC50 8.0 – 8.6 [37]
peptide YY {Sp: Human} Rn Full agonist 7.6 – 8.5 pIC50 15,37
pIC50 7.6 – 8.5 [15,37]
[Leu31,Pro34]PYY (pig) Rn Full agonist 7.4 pIC50 15
pIC50 7.4 [15]
NPY-(2-36) (pig) Rn Full agonist 6.3 pIC50 15
pIC50 6.3 [15]
[Ala31,Aib32]NPY (pig) Hs Full agonist 6.0 pIC50 7
pIC50 6.0 [7]
neuropeptide Y {Sp: Human, Mouse, Rat} Hs Agonist - -
peptide YY {Sp: Human} Hs Agonist - -
View species-specific agonist tables
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[125I]GR231118 Rn Antagonist 10.0 pKd 15
pKd 10.0 [15]
GR231118 Rn Antagonist 10.9 pKi 20
pKi 10.9 [20]
BIBP3226 Hs Antagonist 8.1 – 9.3 pKi 14,71
pKi 8.1 – 9.3 (Ki 7.6x10-9 – 4.7x10-10 M) [14,71]
SR120819A Hs Antagonist 8.4 pKi 60
pKi 8.4 [60]
BIBP3226 Rn Antagonist 7.9 – 8.5 pKi 14,20,28
pKi 7.9 – 8.5 [14,20,28]
BIBO3304 Rn Antagonist 9.7 pIC50 15
pIC50 9.7 [15]
BIBO3304 Hs Antagonist 9.5 pIC50 70
pIC50 9.5 (IC50 3.8x10-10 M) [70]
GR231118 Rn Antagonist 9.5 pIC50 15
pIC50 9.5 [15]
View species-specific antagonist tables
Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Adenylate cyclase inhibition
References:  27,37,47,67
Tissue Distribution
Colon, kidney, adrenal gland, heart, placenta.
Species:  Human
Technique:  in situ hybridisation.
References:  68
Heart.
Species:  Human
Technique:  Immunohistochemistry.
References:  31
Pial vessels, intracortical microvessels, capillaries.
Species:  Human
Technique:  RT-PCR.
References:  1
CNS: cortex, hippocampus, striatum, hypothalamus, amygdala.
Species:  Human
Technique:  in situ hybridisation.
References:  6
Colon (nonepithelial tissue).
Species:  Rat
Technique:  RT-PCR.
References:  22
Catecholaminergic neurons of the medulla oblongata.
Species:  Rat
Technique:  immunocytochemistry.
References:  72
Aorta, tail artery, hypothalamus, femoral artery, pulmonary artery, renal artery.
Species:  Rat
Technique:  RT-PCR.
References:  4
Ventrolateral portion of the suprachiasmatic nucleus.
Species:  Rat
Technique:  in situ hybridisation.
References:  40
Brain: cortex, hippocampus, thalamus, specific nuclei of the hypothalamus (such as supraoptic and arcuate), amygdala and brainstem nuclei.
Species:  Rat
Technique:  in situ hybridisation.
References:  52
Small arteries and arterioles: in the thyroid and parathyroid glands, spleen, gastrointestinal tract, salivary glands, pancreas, trachea, bladder, reproductive system.
Species:  Rat
Technique:  Immunohistochemistry.
References:  46
Antrum, small intestine, proximal colon.
Species:  Rat
Technique:  RT-PCR.
References:  18
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of cAMP levels in COS-1 cells transfected with the human Y1 receptor.
Species:  Human
Tissue:  COS-1 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  39
Measurement of cAMP levels in HEK 293 cells transfected with the rat Y1 receptor.
Species:  Rat
Tissue:  HEK 293 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  37
Measurement of Ca2+ levels in COS-1 cells transfected with the human Y1 receptor.
Species:  Human
Tissue:  COS-1 cells.
Response measured:  Ca2+ influx.
References:  39
Measurement of Ca2+ levels in HEK 293 cells transfected with the rat Y1 receptor.
Species:  Rat
Tissue:  HEK 293 cells.
Response measured:  Ca2+ influx.
References:  37
Measurement of Ca2+ levels in CHO cells transfected with the human Y1 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Increase in intracellular Ca2+.
References:  27
Measurement of cAMP levels in the mouse adrenocortical Y-1 cell line endogenously expressing the Y1 receptor.
Species:  Mouse
Tissue:  Adrenocortical Y-1 cell line.
Response measured:  Inhibition of cAMP accumulation.
References:  67
Physiological Functions
Modulation of food intake.
Species:  Rat
Tissue:  In vivo.
References:  32
Inhibition of noradrenaline release.
Species:  Rat
Tissue:  Hypothalamus and medulla.
References:  25
Hyperinsulinemia independent of food ingestion.
Species:  Rat
Tissue:  In vivo.
References:  19
Stimulation of ethanol consumption.
Species:  Mouse
Tissue:  In vivo.
References:  61
Increase in blood pressure.
Species:  Rat
Tissue:  In vivo.
References:  2,9,23
Increase in heart rate.
Species:  Rat
Tissue:  In vivo.
References:  73
Antinociception.
Species:  Rat
Tissue:  In vivo.
References:  41,45,63,65-66,74
Modulation of anxiety-related behaviour.
Species:  Rat
Tissue:  In vivo.
References:  36,62
Stimulation of LH release.
Species:  Rat
Tissue:  In vivo.
References:  30
Stimulation of aldosterone secretion.
Species:  Rat
Tissue:  Adrenal capsular tissue.
References:  57
Inhibition of electrogenic ion transport.
Species:  Human
Tissue:  Isolated descending colon.
References:  13
Inhibition of electrogenic ion transport.
Species:  Mouse
Tissue:  Colonic mucosal preparaions.
References:  11
Physiological Consequences of Altering Gene Expression
Y1 receptor knockout mice exhibit diet-induced obesity.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  58
Y1 receptor knockout mice exhibit obesity and hyperinsulinemia.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  5,38
The feeding behaviour of Y1 receptor knockout mice is unaltered following antagonist administration, unlike in wild-type mice where feeding is suppressed.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  32
Y1 receptor knockout mice do not exhibit potentiation of pentobarbital-induced sedation, as seen in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  49-50
Y1 receptor knockout mice exhibit an increase in ethanol consumption.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  64
In response to fasting, Y1 receptor knockout mice do not exhibit an impairment of reproductive function (measured as pituitary LH content and weight of seminal vesicles), as seen in fasted wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  56
Y1 receptor knockout mice exhibit impaired sensing of poor metabolic conditions by the gonadotrope axis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  21
Y1 receptor knockout mice exhibit an increased territorial aggressive behaviour.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  35
Y1 receptor knockout mice exhibit a lack of blood pressure response to NPY, reduced fast-induced refeeding and an increase in body fat.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  54
Y1 receptor knockout mice exhibit a reduced somatomotor reactivity, reduced basal heart rate, increased heart rate activation during social challenge, an increase in the number of α2-adrenoceptors in the dorsal motor nucleus of the vagus and the locus coeruleus and a larger volume fraction of myocardial fibrosis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  10
The dentate gyrus of Y1 receptor knockout mice exhibit reduced cell proliferation and fewer immature doublecortin-positive neurons.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  29
Y1 receptor knockout mice exhibit stress exposure and circadian rhythm-dependent changes in motor activity, exploration, and anxiety.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  34
T cells from Y1 receptor knockout mice exhibit hyperresponsive. Y1 receptor knockout mice are resistant to Th1 cell-mediated inflammatory responses, show reduced levels of the Th1 cell-promoting cytokine Il-12 and reduced IFN-γ production.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  69
Y1 receptor knockout mice exhibit mechanical pain hypersensitivity. Following peripheral nerve injury they exhibit an increase in synthesis, transport and release of CGRP and substance P in the dorsal horn.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  59
Y1 receptor knockout mice exhibit an altered susceptibility to chemically-induced seizures.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  42
Y1 receptor knockout mice exhibit an increase in catecholamine synthesis and secretion from the adrenal medulla.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  8
Y1 receptor knockout mice exhibit half as many dividing olfactory neuronal precursor cells and fewer olfactory neurons compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  24
Y1 receptor knockout mice exhibit hyperalgesia.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  51
Y1 receptor knockout mice exhibit reduced NPY-induced food intake, compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  33
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0004185 abnormal adipocyte glucose uptake PMID: 11287097 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0002452 abnormal antigen presenting cell physiology PMID: 16330815 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0001544 abnormal cardiovascular system physiology PMID: 15652259 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0005450 abnormal energy expenditure PMID: 9623984 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0002078 abnormal glucose homeostasis PMID: 11287097 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0005437 abnormal glycogen level PMID: 11287097 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0001819 abnormal immune cell physiology PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0002722 abnormal immune system organ morphology PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0001790 abnormal immune system physiology PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0002490 abnormal immunoglobulin level PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0001845 abnormal inflammatory response PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008828 abnormal lymph node cell ratio PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0002451 abnormal macrophage physiology PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0009937 abnormal neuron differentiation PMID: 12859678 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: C57BL/6
MGI:104963  MP:0006092 abnormal olfactory neuron morphology PMID: 18305161 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: C57BL/6
MGI:104963  MP:0004275 abnormal postnatal subventricular zone morphology PMID: 18305161 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: C57BL/6
MGI:104963  MP:0004279 abnormal rostral migratory stream morphology PMID: 18305161 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0000689 abnormal spleen morphology PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008826 abnormal splenic cell ratio PMID: 16330815 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0001007 abnormal sympathetic system morphology PMID: 15652259 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0001828 abnormal T cell activation PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0006387 abnormal T cell number PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0005465 abnormal T-helper 1 physiology PMID: 16330815 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0000250 abnormal vasoconstriction PMID: 9623984 
Npy1rtm1Pern|Npy2rtm1Pern Npy1rtm1Pern/Npy1rtm1Pern,Npy2rtm1Pern/Npy2rtm1Pern
involves: 129/Sv
MGI:104963  MGI:108418  MP:0002862 altered righting response PMID: 11579129 
Npy1rtm1Pern Npy1rtm1Pern/Npy1rtm1Pern
Not Specified
MGI:104963  MP:0002862 altered righting response PMID: 11579129 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0005608 cardiac interstitial fibrosis PMID: 15652259 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0005017 decreased B cell number PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008079 decreased CD8-positive T cell number PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008618 decreased circulating interleukin-12 level PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008554 decreased circulating tumor necrosis factor level PMID: 16330815 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0003910 decreased eating behavior PMID: 9623984 
Npy1rtm1Aka Npy1rtm1Aka/Npy1rtm1Aka
involves: C57BL/6 * CBA
MGI:104963  MP:0003910 decreased eating behavior PMID: 10698177 
Npy1rtm1Mnak Npy1rtm1Mnak/Npy1rtm1Mnak
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0004890 decreased energy expenditure PMID: 9861026 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0001417 decreased exploration in new environment PMID: 15652259 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0005333 decreased heart rate PMID: 15652259 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008496 decreased IgG2a level PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008567 decreased interferon-gamma secretion PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008182 decreased marginal zone B cell number PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008211 decreased mature B cell number PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: C57BL/6
MGI:104963  MP:0004981 decreased neuronal precursor cell number PMID: 18305161 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0005290 decreased oxygen consumption PMID: 9623984 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0009767 decreased sensitivity to xenobiotic induced morbidity/mortality PMID: 16650144 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0005616 decreased susceptibility to type IV hypersensitivity reaction PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008190 decreased transitional stage B cell number PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0001399 hyperactivity PMID: 15314215 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0001559 hyperglycemia PMID: 11287097 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0001402 hypoactivity PMID: 9623984 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0009755 impaired behavioral response to alcohol PMID: 11826154 
Npy1rtm1Mnak Npy1rtm1Mnak/Npy1rtm1Mnak
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0005293 impaired glucose tolerance PMID: 9861026 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0001353 increased aggression towards mice PMID: 15314215 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0003545 increased alcohol consumption PMID: 11826154 
Npy1rtm1Mnak Npy1rtm1Mnak/Npy1rtm1Mnak
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0001260 increased body weight PMID: 9861026 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008074 increased CD4-positive T cell number PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008078 increased CD8-positive T cell number PMID: 16330815 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0001745 increased circulating corticosterone level PMID: 14525913 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0001554 increased circulating free fatty acid level PMID: 9623984 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0002079 increased circulating insulin level PMID: 9623984 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0002079 increased circulating insulin level PMID: 11287097  14525913 
Npy1rtm1Mnak Npy1rtm1Mnak/Npy1rtm1Mnak
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0002079 increased circulating insulin level PMID: 9861026 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0005669 increased circulating leptin level PMID: 9623984 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0005669 increased circulating leptin level PMID: 14525913 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0009288 increased epididymal fat pad weight PMID: 11287097 
Npy1rtm1Mnak Npy1rtm1Mnak/Npy1rtm1Mnak
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0009285 increased gonadal fat pad weight PMID: 9861026 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0002495 increased IgA level PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008501 increased IgG2b level PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0002494 increased IgM level PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0002461 increased immunoglobulin level PMID: 16330815 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0001934 increased litter size PMID: 15314215 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0005458 increased percent body fat PMID: 11287097 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0009304 increased retroperitoneal fat pad weight PMID: 14525913 
Npy1rtm1Mnak Npy1rtm1Mnak/Npy1rtm1Mnak
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0009304 increased retroperitoneal fat pad weight PMID: 9861026 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0008082 increased single-positive T cell number PMID: 16330815 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0010024 increased total body fat amount PMID: 9623984 
Npy1rtm1Wpg Npy1rtm1Wpg/Npy1rtm1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0002169 no abnormal phenotype detected PMID: 12859678 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
involves: 129P2/OlaHsd * C57BL/6
MGI:104963  MP:0001261 obese PMID: 9623984 
Npy1rtm1Tped Npy1rtm1Tped/Npy1rtm1Tped
B6.129P2-Npy1r
MGI:104963  MP:0001261 obese PMID: 14525913 
Npy1rtm1Aka Npy1rtm1Aka/Npy1rtm1Aka
involves: C57BL/6 * CBA
MGI:104963  MP:0001261 obese PMID: 10698177 
Npy1rtm1.1Wpg Npy1rtm1.1Wpg/Npy1rtm1.1Wpg
involves: 129X1/SvJ * C57BL/6
MGI:104963  MP:0000692 small spleen PMID: 16330815 
Biologically Significant Variants
Type:  Splice variants
Species:  Human
Description:  Three splice variants of the human Y1 receptor have been identified which yield multiple promoters with tissue-specific expression patterns.
References:  3
Type:  Splice variants
Species:  Mouse
Description:  Two splice variants exist for the murine Y1 receptor, one of which has a shortened TM7 and lacks the C-terminus. This variant binds NPY but couples less effectively to signal transduction
References:  48
General Comments
For a review on NPY receptor knockout mice see [43].
For a review specifically on Y1 receptor knockouts see [53].

References

Show »

1. Abounader R, Elhusseiny A, Cohen Z, Olivier A, Stanimirovic D, Quirion R, Hamel E. (1999) Expression of neuropeptide Y receptors mRNA and protein in human brain vessels and cerebromicrovascular cells in culture. J Cereb Blood Flow Metab, 19: 155-163. [PMID:10027771]

2. Abrahamsson C. (2000) Neuropeptide Y1- and Y2-receptor-mediated cardiovascular effects in the anesthetized guinea pig, rat, and rabbit. J Cardiovasc Pharmacol, 36: 451-458. [PMID:11026645]

3. Ball HJ, Shine J, Herzog H. (1995) Multiple promoters regulate tissue-specific expression of the human NPY-Y1 receptor gene. J. Biol. Chem., 270: 27272-27276. [PMID:7592987]

4. Barrios VE, Sun J, Douglass J, Toombs CF. (1999) Evidence of a specific pancreatic polypeptide receptor in rat arterial smooth muscle. Peptides, 20: 1107-1113. [PMID:10499429]

5. Burcelin R, Brunner H, Seydoux J, Thorensa B, Pedrazzini T. (2001) Increased insulin concentrations and glucose storage in neuropeptide Y Y1 receptor-deficient mice. Peptides, 22: 421-427. [PMID:11287097]

6. Caberlotto L, Fuxe K, Rimland JM, Sedvall G, Hurd YL. (1998) Regional distribution of neuropeptide Y Y2 receptor messenger RNA in the human post mortem brain. Neuroscience, 86: 167-178. [PMID:9692752]

7. Cabrele C, Wieland HA, Koglin N, Stidsen C, Beck-Sickinger AG. (2002) Ala31-Aib32: identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-receptor. Biochemistry, 41: 8043-8049. [PMID:12069595]

8. Cavadas C, Céfai D, Rosmaninho-Salgado J, Vieira-Coelho MA, Moura E, Busso N, Pedrazzini T, Grand D, Rotman S, Waeber B, Aubert JF, Grouzmann E. (2006) Deletion of the neuropeptide Y (NPY) Y1 receptor gene reveals a regulatory role of NPY on catecholamine synthesis and secretion. Proc Natl Acad Sci U S A, 103: 10497-10502. [PMID:16798884]

9. Coppes RP, Smit J, Geurtsen AM, Roffel AF, Dahlöf C, Doods HN, Zaagsma J. (1994) Heterogeneity of prejunctional neuropeptide Y receptors inhibiting noradrenaline overflow in the portal vein of freely moving rats. Eur J Pharmacol, 261: 311-316. [PMID:7813553]

10. Costoli T, Sgoifo A, Stilli D, Flugge G, Adriani W, Laviola G, Fuchs E, Pedrazzini T, Musso E. (2005) Behavioural, neural and cardiovascular adaptations in mice lacking the NPY Y1 receptor. Neurosci Biobehav Rev, 29: 113-123. [PMID:15652259]

11. Cox HM, Pollock EL, Tough IR, Herzog H. (2001) Multiple Y receptors mediate pancreatic polypeptide responses in mouse colon mucosa. Peptides, 22: 445-452. [PMID:11287100]

12. Cox HM, Tough IR. (1995) Functional characterization of receptors with affinity for PYY, NPY, [Leu31,Pro34]NPY and PP in a human colonic epithelial cell line. Br. J. Pharmacol., 116 (6): 2673-8. [PMID:8590988]

13. Cox HM, Tough IR. (2002) Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa. Br J Pharmacol, 135: 1505-1512. [PMID:11906964]

14. Doods HN, Wienen W, Entzeroth M, Rudolf K, Eberlein W, Engel W, Wieland HA. (1995) Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J. Pharmacol. Exp. Ther., 275 (1): 136-42. [PMID:7562541]

15. Dumont Y, Quirion R. (2000) [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors. Br J Pharmacol, 129: 37-46. [PMID:10694200]

16. Eva C, Keinänen K, Monyer H, Seeburg P, Sprengel R. (1990) Molecular cloning of a novel G protein-coupled receptor that may belong to the neuropeptide receptor family. FEBS Lett, 271: 81-84. [PMID:2172008]

17. Eva C, Oberto A, Sprengel R, Genazzani E. (1992) The murine NPY-1 receptor gene. Structure and delineation of tissue-specific expression. FEBS Lett, 314: 285-288. [PMID:1468559]

18. Ferrier L, Segain JP, Bonnet C, Cherbut C, Lehur PA, Jarry A, Galmiche JP, Blottiere HM. (2002) Functional mapping of NPY/PYY receptors in rat and human gastro-intestinal tract. Peptides, 23: 1765-1771. [PMID:12383864]

19. Gao J, Ghibaudi L, Hwa JJ. (2004) Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms. Am J Physiol Endocrinol Metab, 287: E706-E711. [PMID:15187000]

20. Gehlert DR, Schober DA, Gackenheimer SL, Beavers L, Gadski R, Lundell I, Larhammar D. (1997) [125I]Leu31, Pro34-PYY is a high affinity radioligand for rat PP1/Y4 and Y1 receptors: evidence for heterogeneity in pancreatic polypeptide receptors. Peptides, 18: 397-401. [PMID:9145427]

21. Gonzales C, Voirol MJ, Giacomini M, Gaillard RC, Pedrazzini T, Pralong FP. (2004) The neuropeptide Y Y1 receptor mediates NPY-induced inhibition of the gonadotrope axis under poor metabolic conditions. FASEB J, 18: 137-139. [PMID:14597564]

22. Goumain M, Voisin T, Lorinet AM, Laburthe M. (1998) Identification and distribution of mRNA encoding the Y1, Y2, Y4, and Y5 receptors for peptides of the PP-fold family in the rat intestine and colon. Biochem Biophys Res Commun, 247: 52-56. [PMID:9636652]

23. Han S, Chen X, Cox B, Yang CL, Wu YM, Naes L, Westfall T. (1998) Role of neuropeptide Y in cold stress-induced hypertension. Peptides, 19: 351-358. [PMID:9493868]

24. Hansel DE, Eipper BA, Ronnett GV. (2001) Neuropeptide Y functions as a neuroproliferative factor. Nature, 410: 940-944. [PMID:11309620]

25. Hastings JA, Morris MJ, Lambert G, Lambert E, Esler M. (2004) NPY and NPY Y1 receptor effects on noradrenaline overflow from the rat brain in vitro. Regul Pept, 120: 107-112. [PMID:15177927]

26. Herzog H, Baumgartner M, Vivero C, Selbie LA, Auer B, Shine J. (1993) Genomic organization, localization, and allelic differences in the gene for the human neuropeptide Y Y1 receptor. J Biol Chem, 268: 6703-6707. [PMID:8095935]

27. Herzog H, Hort YJ, Ball HJ, Hayes G, Shine J, Selbie LA. (1992) Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc Natl Acad Sci U S A, 89: 5794-5798. [PMID:1321422]

28. Holliday ND, Cox HM. (1996) The functional investigation of a human adenocarcinoma cell line, stably transfected with the neuropeptide Y Y1 receptor. Br J Pharmacol, 119: 321-329. [PMID:8886416]

29. Howell OW, Doyle K, Goodman JH, Scharfman HE, Herzog H, Pringle A, Beck-Sickinger AG, Gray WP. (2005) Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J Neurochem, 93: 560-570. [PMID:15836615]

30. Jain MR, Pu S, Kalra PS, Kalra SP. (1999) Evidence that stimulation of two modalities of pituitary luteinizing hormone release in ovarian steroid-primed ovariectomized rats may involve neuropeptide Y Y1 and Y4 receptors. Endocrinology, 140: 5171-5177. [PMID:10537146]

31. Jönsson-Rylander AC, Nordlander M, Svindland A, Ilebekk A. (2003) Distribution of neuropeptide Y Y1 and Y2 receptors in the postmortem human heart. Peptides, 24: 255-262. [PMID:12668210]

32. Kanatani A, Hata M, Mashiko S, Ishihara A, Okamoto O, Haga Y, Ohe T, Kanno T, Murai N, Ishii Y, Fukuroda T, Fukami T, Ihara M. (2001) A typical Y1 receptor regulates feeding behaviors: effects of a potent and selective Y1 antagonist, J-115814. Mol Pharmacol, 59: 501-505. [PMID:11179445]

33. Kanatani A, Mashiko S, Murai N, Sugimoto N, Ito J, Fukuroda T, Fukami T, Morin N, MacNeil DJ, Van der Ploeg LH, Saga Y, Nishimura S, Ihara M. (2000) Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology, 141: 1011-1016. [PMID:10698177]

34. Karl T, Burne TH, Herzog H. (2006) Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety. Behav Brain Res, 167: 87-93. [PMID:16203045]

35. Karl T, Lin S, Schwarzer C, Sainsbury A, Couzens M, Wittmann W, Boey D, von Hörsten S, Herzog H. (2004) Y1 receptors regulate aggressive behavior by modulating serotonin pathways. Proc Natl Acad Sci U S A, 101: 12742-12747. [PMID:15314215]

36. Kask A, Rägo L, Harro J. (1998) Anxiogenic-like effect of the NPY Y1 receptor antagonist BIBP3226 administered into the dorsal periaqueductal gray matter in rats. Regul Pept, 75-76: 255-262. [PMID:9802417]

37. Krause J, Eva C, Seeburg PH, Sprengel R. (1992) Neuropeptide Y1 subtype pharmacology of a recombinantly expressed neuropeptide receptor. Mol Pharmacol, 41: 817-821. [PMID:1316999]

38. Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, Nakamura M. (1998) Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad Sci U S A, 95: 15659-15664. [PMID:9861026]

39. Larhammar D, Blomqvist AG, Yee F, Jazin E, Yoo H, Wahlested C. (1992) Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem, 267: 10935-10938. [PMID:1317848]

40. Larsen PJ, Kristensen P. (1998) Distribution of neuropeptide Y receptor expression in the rat suprachiasmatic nucleus. Brain Res Mol Brain Res, 60: 69-76. [PMID:9748510]

41. Li JJ, Zhou X, Yu LC. (2005) Involvement of neuropeptide Y and Y1 receptor in antinociception in the arcuate nucleus of hypothalamus, an immunohistochemical and pharmacological study in intact rats and rats with inflammation. Pain, 118: 232-242. [PMID:16216414]

42. Lin EJ, Young D, Baer K, Herzog H, During MJ. (2006) Differential actions of NPY on seizure modulation via Y1 and Y2 receptors: evidence from receptor knockout mice. Epilepsia, 47: 773-780. [PMID:16650144]

43. Lin S, Boey D, Herzog H. (2004) NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides, 38: 189-200. [PMID:15337371]

44. Lutz CM, Frankel WN, Richards JE, Thompson DA. (1997) Neuropeptide Y receptor genes on human chromosome 4q31-q32 map to conserved linkage groups on mouse chromosomes 3 and 8. Genomics, 41: 498-500. [PMID:9169155]

45. Mahinda TB, Taylor BK. (2004) Intrathecal neuropeptide Y inhibits behavioral and cardiovascular responses to noxious inflammatory stimuli in awake rats. Physiol Behav, 80: 703-711. [PMID:14984805]

46. Matsuda H, Brumovsky PR, Kopp J, Pedrazzini T, Hökfelt T. (2002) Distribution of neuropeptide Y Y1 receptors in rodent peripheral tissues. J Comp Neurol, 449: 390-404. [PMID:12115674]

47. Misra S, Murthy KS, Zhou H, Grider JR. (2004) Coexpression of Y1, Y2, and Y4 receptors in smooth muscle coupled to distinct signaling pathways. J Pharmacol Exp Ther, 311: 1154-1162. [PMID:15308651]

48. Nakamura M, Sakanaka C, Aoki Y, Ogasawara H, Tsuji T, Kodama H, Matsumoto T, Shimizu T, Noma M. (1995) Identification of two isoforms of mouse neuropeptide Y-Y1 receptor generated by alternative splicing. Isolation, genomic structure, and functional expression of the receptors. J. Biol. Chem., 270: 30102-30110. [PMID:8530415]

49. Naveilhan P, Canals JM, Arenas E, Ernfors P. (2001) Distinct roles of the Y1 and Y2 receptors on neuropeptide Y-induced sensitization to sedation. J Neurochem, 78: 1201-1207. [PMID:11579129]

50. Naveilhan P, Canals JM, Valjakka A, Vartiainen J, Arenas E, Ernfors P. (2001) Neuropeptide Y alters sedation through a hypothalamic Y1-mediated mechanism. Eur J Neurosci, 13: 2241-2246. [PMID:11454027]

51. Naveilhan P, Hassani H, Lucas G, Blakeman KH, Hao JX, Xu XJ, Wiesenfeld-Hallin Z, Thorén P, Ernfors P. (2001) Reduced antinociception and plasma extravasation in mice lacking a neuropeptide Y receptor. Nature, 409: 513-517. [PMID:11206547]

52. Parker RM, Herzog H. (1999) Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci, 11: 1431-1448. [PMID:10103138]

53. Pedrazzini T. (2004) Importance of NPY Y1 receptor-mediated pathways: assessment using NPY Y1 receptor knockouts. Neuropeptides, 38: 267-275. [PMID:15337379]

54. Pedrazzini T, Seydoux J, Kunstner P, Aubert J-F, Grouzmann E, Beermann F, Brunner H-R. (1998) Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat. Med., 4: 722-726. [PMID:9623984]

55. Petitto JM, Huang Z, McCarthy DB. (1994) Molecular cloning of NPY-Y1 receptor cDNA from rat splenic lymphocytes: evidence of low levels of mRNA expression and [125I]NPY binding sites. J Neuroimmunol, 54: 81-86. [PMID:7929806]

56. Pralong FP, Gonzales C, Voirol MJ, Palmiter RD, Brunner HR, Gaillard RC, Seydoux J, Pedrazzini T. (2002) The neuropeptide Y Y1 receptor regulates leptin-mediated control of energy homeostasis and reproductive functions. FASEB J, 16: 712-714. [PMID:11978737]

57. Renshaw D, Thomson LM, Carroll M, Kapas S, Hinson JP. (2000) Actions of neuropeptide Y on the rat adrenal cortex. Endocrinology, 141: 169-173. [PMID:10614636]

58. Sainsbury A, Bergen HT, Boey D, Bamming D, Cooney GJ, Lin S, Couzens M, Stroth N, Lee NJ, Lindner D, Singewald N, Karl T, Duffy L, Enriquez R, Slack K, Sperk G, Herzog H. (2006) Y2Y4 receptor double knockout protects against obesity due to a high-fat diet or Y1 receptor deficiency in mice. Diabetes, 55: 19-26. [PMID:16380472]

59. Shi TJ, Li J, Dahlström A, Theodorsson E, Ceccatelli S, Decosterd I, Pedrazzini T, Hökfelt T. (2006) Deletion of the neuropeptide Y Y1 receptor affects pain sensitivity, neuropeptide transport and expression, and dorsal root ganglion neuron numbers. Neuroscience, 140: 293-304. [PMID:16564642]

60. Sjödin P, Holmberg SK, Akerberg H, Berglund MM, Mohell N, Larhammar D. (2006) Re-evaluation of receptor-ligand interactions of the human neuropeptide Y receptor Y1: a site-directed mutagenesis study. Biochem J, 393: 161-169. [PMID:16097949]

61. Sparta DR, Fee JR, Hayes DM, Knapp DJ, MacNeil DJ, Thiele TE. (2004) Peripheral and central administration of a selective neuropeptide Y Y1 receptor antagonist suppresses ethanol intake by C57BL/6J mice. Alcohol Clin Exp Res, 28: 1324-1330. [PMID:15365302]

62. Sørensen G, Lindberg C, Wörtwein G, Bolwig TG, Woldbye DP. (2004) Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation. J Neurosci Res, 77: 723-729. [PMID:15352219]

63. Taiwo OB, Taylor BK. (2002) Antihyperalgesic effects of intrathecal neuropeptide Y during inflammation are mediated by Y1 receptors. Pain, 96: 353-363. [PMID:11973010]

64. Thiele TE, Koh MT, Pedrazzini T. (2002) Voluntary alcohol consumption is controlled via the neuropeptide Y Y1 receptor. J Neurosci, 22: RC208-RC208. [PMID:11826154]

65. Wang JZ, Lundeberg T, Yu L. (2000) Antinociceptive effects induced by intra-periaqueductal grey administration of neuropeptide Y in rats. Brain Res, 859: 361-363. [PMID:10719086]

66. Wang JZ, Lundeberg T, Yu LC. (2001) Anti-nociceptive effect of neuropeptide Y in periaqueductal grey in rats with inflammation. Brain Res, 893: 264-267. [PMID:11223015]

67. Weng G, Yee F, Michl P, Reis D, Wahlestedt C. (1995) Studies on neuropeptide Y receptors in a mouse adrenocortical cell line. Mol Pharmacol, 48: 9-14. [PMID:7623780]

68. Wharton J, Gordon L, Byrne J, Herzog H, Selbie LA, Moore K, Sullivan MH, Elder MG, Moscoso G, Taylor KM. (1993) Expression of the human neuropeptide tyrosine Y1 receptor. Proc Natl Acad Sci U S A, 90: 687-691. [PMID:8421707]

69. Wheway J, Mackay CR, Newton RA, Sainsbury A, Boey D, Herzog H, Mackay F. (2005) A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. J Exp Med, 202: 1527-1538. [PMID:16330815]

70. Wieland HA, Engel W, Eberlein W, Rudolf K, Doods HN. (1998) Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br. J. Pharmacol., 125: 549-555. [PMID:9806339]

71. Wieland HA, Willim KD, Entzeroth M, Wienen W, Rudolf K, Eberlein W, Engel W, Doods HN. (1995) Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226. J. Pharmacol. Exp. Ther., 275 (1): 143-9. [PMID:7562543]

72. Yang SN, Bunnemann B, Cintra A, Fuxe K. (1996) Localization of neuropeptide Y Y1 receptor-like immunoreactivity in catecholaminergic neurons of the rat medulla oblongata. Neuroscience, 73: 519-530. [PMID:8783267]

73. Zhang W, Lundberg JM, Thorén P. (1997) Neuropeptide Y Y1 receptor antagonist (BIBP 3226) attenuates stress evoked tachycardia in conscious spontaneously hypertensive rats. Cardiovasc Drugs Ther, 11: 801-806. [PMID:9512876]

74. Zhang Y, Lundeberg T, Yu L. (2000) Involvement of neuropeptide Y and Y1 receptor in antinociception in nucleus raphe magnus of rats. Regul Pept, 95: 109-113. [PMID:11062340]

Contributors

Show »

How to cite this page

Annette Beck-Sickinger, William F. Colmers, Helen M. Cox, Henri N. Doods, Herbert Herzog, Dan Larhammar, Martin C. Michel, Remi Quirion, Thue Schwartz, Thomas Westfall.
Neuropeptide Y receptors: Y1 receptor. Last modified on 20/02/2018. Accessed on 13/11/2018. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=305.